Search results
Obesity Definitions and LOS in Heart Failure
Added:
1 week ago
Original Research
Added:
2 weeks ago
HFA Congress 2026 — Dr Rui Baptista (University of Coimbra, Coimbra, PT) joins us to discuss findings from the PORTHOS (PORTuguese Heart Failure Observational Study), a nationwide, population-based epidemiological study examining heart failure prevalence and characteristics in mainland Portugal using contemporary diagnostic tools.PORTHOS enrolled 6,189 adults aged 50 and above, randomly selected…
View more
The True Obesity Paradox: Obese and Malnourished?
Added:
1 year ago
Original Research
Added:
8 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT…
View more
Obesity, Cardiac MRI Structure and Non-ischaemic Cardiomyopathy
Added:
1 year ago
Original Research
Added:
10 months ago
In this short interview, we are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) to discuss the key updates and recommendations from the 2025 ACC Scientific Statement on the Management of Obesity in Adults with Heart Failure.Interview Questions:1. What is the current research landscape for heart failure patients with obesity?2. What are the new recommendations in this scientific…
View more
Obesity in Focus
Added:
8 months ago
Video
Added:
11 months ago
In this short interview, Dr Mohammed El-Sheikh discusses the key findings and clinical relevance of his recently published article, “Associations of Obesity and Prognostic Nutritional Index on 1-Year Mortality in Patients with Acute Heart Failure.”
View more
Added:
1 year ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,…
View more
Added:
1 year ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more